Wednesday, April 22, 2009

Does Avastin Trial Mean Roche Paid Too Much for Genentech?

A major Genentech drug, Avastin, failed to meet its main goal in a closely watched trial in colon cancer.
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)